The Cost of Lost Productivity in an Opioid Utilizing Pain Sample

Background and Aims Chronic pain affects more adults in the United States than any other condition. Opioid medications are widely used in the treatment of chronic pain, but there remains considerable risk and cost associated with their use. This study aims to characterize the effects of opioid prescribing for chronic pain and similar pain conditions on lost productivity in the United States. Methods This was a retrospective, longitudinal, observational study of chronic pain patients in 2011–2014. We identified patients with a diagnosis of musculoskeletal pain receiving index prescription for opioids in administrative claims and studied disability absence in a linked health and productivity management database. Patients were grouped as de novo and continued use opioid users before index, and by opioid dose in the year after index. Days of disability were compared before and after index with bootstrapping. Effect of opioid dose group on disability was evaluated with negative binomial regression. Lost productivity cost was compared before and after index. Results The cohort contained 16,273 de novo and 6604 continued use patients. On average, de novo patients used 24.8 days of disability after index, an increase of 18.3 more days compared to before (p < 0.001). Continued use patients used 30.7 days after index, 9 more days than before (p < 0.001). There was a dose–response relationship between dose group and days of disability in de novo patients (p < 0.001). The weighted-average cost per person of lost productivity was $4344 higher in the year after index compared to the year before. Conclusion Opioid prescriptions for pain patients were associated with significant disability use and lost productivity costs. With the evolution of opioid-prescribing practices, CDC recommendations, and the HHS Pain Management Best Practices, there is opportunity to use alternative pain therapies without the risks of opioid-induced side effects to improve work productivity.

[1]  D. Caraway,et al.  10 kHz SCS therapy for chronic pain, effects on opioid usage: Post hoc analysis of data from two prospective studies , 2019, Scientific Reports.

[2]  E. Mittendorfer-Rutz,et al.  Trajectories of sickness absence and disability pension before and after opioid initiation for noncancer pain: a 10-year population-based study , 2019, Pain.

[3]  R. Chou,et al.  No Shortcuts to Safer Opioid Prescribing. , 2019, The New England journal of medicine.

[4]  James M. Dahlhamer,et al.  Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016 , 2018, MMWR. Morbidity and mortality weekly report.

[5]  M. Bushnell,et al.  Prevalence and Profile of High-Impact Chronic Pain in the United States , 2018, The journal of pain : official journal of the American Pain Society.

[6]  L. F. Ribeiro de Azevedo,et al.  The Impact of Anxiety and Depression on the Outcomes of Chronic Low Back Pain Multidisciplinary Pain Management—A Multicenter Prospective Cohort Study in Pain Clinics with One‐Year Follow‐up , 2018, Pain medicine.

[7]  Allison T. Connolly,et al.  Association of Opioid Usage with Spinal Cord Stimulation Outcomes , 2018, Pain medicine.

[8]  K. Slavin,et al.  Success Using Neuromodulation With BURST (SUNBURST) Study: Results From a Prospective, Randomized Controlled Trial Using a Novel Burst Waveform , 2018, Neuromodulation : journal of the International Neuromodulation Society.

[9]  P. Staats,et al.  Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial , 2016, Pain.

[10]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.

[11]  L. Dhingra,et al.  Cognitive Effects and Sedation. , 2015, Pain medicine.

[12]  Karin A Mack,et al.  Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007-2012. , 2015, American journal of preventive medicine.

[13]  Samantha D. Outcalt,et al.  Association between anxiety, health-related quality of life and functional impairment in primary care patients with chronic pain. , 2013, General hospital psychiatry.

[14]  Patrick Richard,et al.  The economic costs of pain in the United States. , 2012, The journal of pain : official journal of the American Pain Society.

[15]  M. Robinson,et al.  The role of psychological interventions in the management of patients with chronic pain , 2011, Psychology research and behavior management.

[16]  Matt Schiller,et al.  Societal costs of prescription opioid abuse, dependence, and misuse in the United States. , 2011, Pain medicine.

[17]  D. Knol,et al.  Randomised controlled trial of integrated care to reduce disability from chronic low back pain in working and private life , 2010, BMJ : British Medical Journal.

[18]  T. Mayer,et al.  Higher opioid doses predict poorer functional outcome in patients with chronic disabling occupational musculoskeletal disorders. , 2009, The Journal of bone and joint surgery. American volume.

[19]  E. Bruera,et al.  Critical issues on opioids in chronic non-cancer pain: An epidemiological study , 2006, Pain.

[20]  P. Staats,et al.  The psychological behaviorism theory of pain and the placebo: its principles and results of research application. , 2006, Advances in psychosomatic medicine.

[21]  J. Mao,et al.  Opioid therapy for chronic pain. , 2003, The New England journal of medicine.

[22]  H. Sutton.  AN EPIDEMIOLOGICAL STUDY , 1937 .

[23]  Lee S. Simon.  RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, CARE, EDUCATION, AND RESEARCH , 2012, Military medicine.

[24]  A. Banerjee,et al.  A 10-year population-based study of ischaemic peripheral arterial events: implications for primary prevention , 2015 .